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ABSTRACT

End-stage renal disease is a rising health care problem affecting more than 15% of the United
States population. There are 700,000 patients with renal disease in the United States characterized
by multiple comorbidities and increasing, distressing symptom burden. The necessity for
palliative care for patients with end-stage renal disease is becoming the standard of care due to
their complex medical needs and high symptom burden. The aim of this integrative review was to
investigate the existing literature that evaluated the incorporation of palliative care to improve the
quality of life of patients with end-stage renal disease. The goal of conducting this integrative
review was to explore the benefit of integrating palliative care for patients with end-stage renal
disease to improve their overall quality of life.

Keywords: Palliative care, end-stage-renal disease, improved symptom management,
quality of life
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PALLIATIVE CARE AND IMPROVING QUALITY OF LIFE WITH END STAGE
RENAL DISEASE: AN INTEGRATIVE REVIEW
SECTION ONE: FORMULATING THE REVIEW QUESTION

Chronic kidney disease poses a significant public health problem in the United States.
Chronic kidney disease and end-stage renal disease continue to rise annually, costing millions in
Medicare dollars (Grubbs, 2018). Both chronic kidney disease and end-stage renal disease confer
significant mortality and morbidity to those affected by the disease. End-stage renal disease also
causes patients significant symptom burden on those it affects, impacting patients’ quality of life
on many different levels and impacting patients mental, physical, and emotional health.
The Center for Disease Control and Prevention (CDC) defines chronic kidney disease as a
condition in which the kidneys are injured and subsequently are unable to filter waste from the
blood (2021). As defined by the CDC, end-stage renal disease is renal failure lasting greater than
three months, requiring renal replacement therapy or renal transplant as a treatment modality to
maintain a healthy life (2020). As a result, renal replacement therapy and renal transplants have
contributed to increased healthcare expenses. Approximately 350 people every 24 hours in the
United States begin treatment for kidney failure (Carney, 2020). Additionally, a decade ago, it
was reported that the treatment of chronic renal disease to Medicare recipients costs over $84
billion. In comparison, treatment of end-stage renal disease costs an additional $36 billion due to
renal replacement therapy needs (Ozieh et al., 2017).
The CDC and the National Kidney Foundation (2021) report that 15% of the U.S. adult
population, approximately 37 million people, suffer from chronic kidney disease, while millions
of others are at increased risk of developing end-stage renal disease. The CDC states that chronic
kidney disease has risen from the world’s 13th leading cause of death to the world’s ninth leading
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cause of death. Chronic kidney disease and end-stage renal disease cause many health problems
that lead to increased risk of mortality and morbidity.
Background
A 2018 study identified 700,000 patients suffering from renal disease, which led to
patients receiving hemodialysis for treatment for their failing kidneys (Li et al., 2018). As a result
of end-stage renal disease, patients experience dry and itchy skin, restless leg syndrome,
insomnia, fatigue, and joint and chest pain. If a kidney transplant is not available, end-stage renal
disease can eventually lead to death. O’Hare et al. (2017) revealed that these symptoms are
exacerbated by the lack of symptom management received by patients with end-stage renal
disease, resulting in a short life expectancy, development of comorbidities, and poor quality of
life, which may be enhanced with palliative care.
Palliative care is a specialized type of medical care delivered by providers trained to help
people living with chronic diseases (Sturgill & Bear, 2019). This specialized treatment can help
ease pain and suffering experienced by patients due to end-stage renal disease diagnosis (National
Kidney Foundation, 2021). Furthermore, palliative care helps patients and their families
understand their medical condition, prognosis, treatment goals, expectations of the care received
and helps maintain their quality of life throughout their disease process. According to the World
Health Organization (WHO), improved quality of life in any chronic disease state may be
obtained by alleviating the strain and burdens of living with a severe medical condition (2020).
The goal of this integrative review was to determine whether palliative care can help to improve
the quality of life in those patients with end-stage renal disease.
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Defining Concepts
Concepts that need to be defined for the purpose of this integrative review include
palliative care, chronic kidney disease, end-stage renal disease, renal replacement therapy,
hemodialysis, and symptom management. In this integrative review, palliative care has been
described as a type of medical care that improves patients' quality of life and their families'
understanding of disease processes when dealing with severe medical conditions such as endstage renal disease (WHO, 2020). Palliative care is a holistic approach that provides relief from
life-threatening illness through early identification and impeccable assessment and treatment of
pain and other physical, psychosocial, and spiritual health problems. The palliative care goal is to
improve the patient and the families' overall experience when dealing with their complex medical
illness (Chiu et al., 2021).
Chronic kidney disease is defined as a slow progression of kidney damage leading to
kidney failure caused by several underlying disease processes. Chronic kidney disease is a slow
progression in which the kidneys are injured and subsequently are unable to filter waste from the
blood (CDC, 2021). Chronic kidney disease, if not slowed, may lead to end-stage renal failure. If
renal failure occurs, patients may require renal replacement therapy or kidney transplant as a
treatment modality to maintain a healthy life (CDC 2020). End-stage renal disease impacts
patients’ quality of life due to the increased symptom burden of the disease.
Renal replacement therapy is a treatment method therapy that replaces the normal bloodfiltering function of the kidneys for patients with end-stage renal disease. It is used when the
kidneys are not working, also known as kidney failure, and includes acute kidney injury and
chronic kidney disease (National Kidney Foundation 2021).
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For this integrative review, hemodialysis is a form of renal replacement therapy where a
machine called a dialyzer filter, or an artificial kidney is used to clean the blood. To get access to
a blood vessel patient, a doctor needs to make access or entrance into the blood vessels to be
dialyzed. Placing an entry is done with minor surgery, usually to the arm or a large vein in the
body (National Kidney Foundation, 2021). Quality of life is defined as the level of comfort,
health, and happiness experienced by an individual or a group (Britannica, 2020).
Symptom management is the control of a host of complaints experienced by a patient or
witnessed by a patient's family or loved ones. These symptoms can vary and include pain,
especially in the joints and chest, itching, fatigue, poor appetite, trouble concentrating, problem
sleeping, muscle cramping, swollen feet and ankles, and nausea (National Kidney Foundation,
2021).
Rationale for Conducting the Review
According to the National Hospice and Palliative Care Organization (2021), palliative care
is a care model of compassion and education focusing on improving the quality of life for patients
with a life-limiting illness. It focuses on caring for the patient by providing for the patient's
physical, psychosocial, existential, and spiritual health needs (Grubbs 2018). This approach to
care ensures that dignity and quality of life are preserved during active care, especially for those
patients with end-stage renal disease who undergo renal replacement therapy such as
hemodialysis, peritoneal dialysis, or waiting for transplantation as the primary treatment (Grubbs
2018).
Patients with end-stage renal disease requiring renal replacement therapy treatments
experience a heavy symptom burden. The median number of symptoms experienced by patients
with end-stage renal disease is nine, with greater than 60 to 70% of those patients reporting
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symptoms of dry skin, fatigue, itching, and bone/joint pain, with bone and chest pain as the most
frequently occurring symptom (Li et al. 2018). Increased pain may lead to lower quality of life
and, if left untreated, may lead to early death (Pham et al. 2017).
Palliative care provides an ideal opportunity to assess the wellness factors associated with
end-stage renal disease and positively address them to provide comfort for patients undergoing
treatment for end-stage renal disease (O'Halloran et al. 2018). Regrettably, palliative care has
been sub-optimally utilized for patients with end-stage renal disease, thus causing increased
patient suffering and poor quality of life (Li et al. 2018). Less than 20% of Medicare beneficiaries
with end-stage renal disease receive palliative care referrals or interventions during an acute
hospital admission, even when experiencing a worsening of symptoms (Sturgill & Bear 2019).
The history of palliative care is rooted in oncology because, at advanced stages, patients
accept their mortality and forego treatments that postpone the inevitable and elect treatment which
alleviates suffering (Cervantes Blanco & Jones 2017). Palliative care for patients with cancer has
become a standard of oncologic care because it has been proven to be a clinical benefit in the
alleviation of symptom burden, the enhancement of illness, understanding of disease process, and
improvement of both the quality of life and overall survival for patients (Basch et al. 2016; Temel
et al. 2017). The goal of conducting this integrative review was to explore the benefit of
integrating palliative care for patients with end-stage renal disease to improve their overall quality
of life.
Purpose and Review Questions
This integrative review was conducted to address the relationship between palliative care
and quality of life of patients with end-stage renal disease. The aim was to investigate if the
incorporation of palliative care would show an improvement in the quality of life of patients with
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end-stage renal disease once introduced in their care (Taylor et al. 2016). This integrative review
addressed the following clinical question: Does palliative care improve the quality of life in
patients with end-stage renal disease?
Inclusion and Exclusion Criteria
The inclusion criteria for the literature review for this integrative review included studies
written in English, studies that are peered reviewed, research that includes adult patients
diagnosed with end-stage renal disease, which are patients diagnosed with stage four and five
renal diseases, literature written in the last five years (2015-2021), patients requiring renal
replacement therapy, and patients seen in both the acute care and outpatient setting. Databases
searched included Cumulative Index of Nursing and Allied Health Literature (CINAHL) with
PLUS Full Text, Medline, ProQuest Nursing and Allied Health Database, and PubMed.
Keywords used in the search were end-stage renal disease, palliative care, symptom burden,
quality of life, and improved symptom management. Research articles that were selected were
published in the English language and published between the years 2015 to 2021 to ensure the use
of the most current literature.
The exclusion criteria for this integrative literature review were the pediatric patient
population and the patients with renal disease who were not diagnosed with end-stage renal
disease (i.e., not receiving renal replacement therapy, renal disease stage two through three),
publication before 2015 as data may be too old to align with the current study, and no use of data
from editorials or news blogs to avoid biases and to avoid opinion-based data.
Conceptual Framework
This integrative review consisted of a rigorous, higher-level literature review using
conceptual methods described by Whittemore & Knafl (2005). The integrative review is a
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framework used to direct project leaders towards evidence-based practice change by extracting
data and information from different sources of current literature. The model of an integrative
review is essential to the practice of nursing research as it is the only form of research that
combines multiple methodologies (both experimental and nonexperimental), as well as empirical
and theological sources for more rigorous data capturing that plays a role in the improvement of
evidence-based nursing practice (Whittemore & Knafl 2005).
Cooper (2021) explains that the purpose of an integrative review is to provide a summary
of past research that addresses the phenomenon of the current problem which was investigated.
The integrative review synthesizes published literature, both empirical and theoretical, that
supports the integrative review topic. This literature review for this scholarly integrative review
compiled evidence that suggested that palliative care impacts and improves the quality of life for
patients with end-stage renal disease. The study supported the need to raise awareness for the
subject matter via a five-stage synthesis process as defined: (a) problem formulation or
identification of the patients’ needs; (b) where the author reviews the literature to find what the
literature says about the related topic; (c) data evaluation, compiling data from different resources,
different literature sources on the topic of “end-stage renal disease and quality of life”; (d)
analysis and interpretation, the formation of the literature matrix; and (e) presentation of the
results or presenting the data to nephrology and palliative medicine as to the results of the
literature matrix and a literature review (Whittemore & Knafl 2005). Toronto & Remington
(2020) describe an integrative review as a type of research that looks broadly at a phenomenon of
interest and allows for more diverse analysis from many different sources on a specific topic.
The aim of an integrative review involves a theoretical and methodological literature
search to address the objective of the selected integrative review. The integrative review provides

PALLIATIVE CARE AND END-STAGE RENAL DISEASE

14

the project leader with a more holistic understanding of their chosen area of research. According
to Toronto & Remington, steps exist which should be followed by the project leader, which
allowed for a well-developed integrative review (2020). The steps to follow when developing an
integrative review as outlined are to first identify the current state of evidence; second, verify the
quality of the evidence; third, find out what the gaps in the literature are; and finally, identify the
future needs for research and practice development.
A PRISMA Diagram was used to show the results of how an integrative review was used
to collect and categorize the results from the literature search process. The Melnyk’s Level of
Evidence tool was also used to level the literature and research to ensure that the studies were
appraised for strength, content, and good quality (Melnyk & Fineout-Overholt 2015).

SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH

Search Organization and Organization and Reporting Strategies
According to Whittemore and Knafl (2005), search strategies must be defined and
documented to ensure enhanced rigor and unbiased results that will support the review process.
The purpose of a comprehensive literature review is to provide literature sources that best
address the topic being investigated. The information sources and eligibility criteria for this
scholarly project were defined comprehensively. The literature review started with the support of
the Liberty University librarian, who helped with the narrowing of critical terms, the
organization of wording, and advanced search techniques, which increased the rigor of search.
The severity of the investigation was supplemented by combining words that were used to
broaden the literature search to evaluate and critique the literature and methods used in the
development of the analysis table.
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Database Searches
The integrative review search strategy utilized in this research entailed a comprehensive
computer-assisted search using the Jerry Falwell Library selected databases. The search engines
included Cumulative Index of Nursing and Allied Health Literature (CINAHL) with PLUS Full
Text, Medline, ProQuest Nursing and Allied Health Database, and PubMed. Keywords used in
the search were: end-stage renal disease, palliative care, symptom burden, quality of life, and
improved symptom management. Research articles that were selected were published in the
English language and published between the years 2015 to 2021 to ensure the use of the most
current literature.

SECTION THREE: MANAGING THE COLLECTED DATA

The research articles that were chosen for the final review maintained the integrity of the
research question, which is, “does palliative medicine improve the quality of life in patients with
end-stage renal failure,” providing an opportunity to evaluate the strength of the literature
(Toronto & Remington, 2005). As a result, reliable studies helped the project leader conduct an
integrative review that, when synthesized, provided accurate results.
The integrative review method was conducted using a comprehensive search process. As
Toronto and Remington (2020) recommended, a citation manager was used to sort, collect, help
identify, and eliminate duplicate studies. The Zotero reference manager was employed to keep
track of research articles for the literature search and management. The initial search generated
791 research articles, of which 131 duplicates were removed, leaving 760 in which 61 were
related to the integrative review topic. After the inclusion and exclusion criteria were applied and
the duplicated studies were removed, 91 full text studies were assessed for eligibility. Of those
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91 studies, 61 were excluded leaving 30 studies which were included in the qualitative synthesis
and included in the final literature matrix (Table 1).

SECTION FOUR: QUALITY APPRAISAL

Sources of Bias
A rigorous literature search was used to evaluate the literature to determine relevance to
palliative care for patients with end-stage renal disease. The study search was conducted using
specific terms cited in the inclusion and exclusion criteria which minimize study bias
(Whittemore & Knafl 2017). Identifying potential risk for bias when conducting an integrative
review, as bias can occur at any point in the research study. Selection, attrition, measurement,
and publication are examples of biases that can occur during an integrative review (Toronto &
Remington 2020). The studies used in this integrative review have been evaluated to be free of
bias.
Internal Validity
The validity of a study is measured by its transferability, credibility, and confirmability of
the research results. Data saturations give credence to the fact of a study, and transferability
means the study's results can be transferred to other situations and whether or not the findings
can be generalized. Credibility ensures that only the findings are addressed, and confirmability
means that others can confirm the results (Toronto & Remington, 2020).
The integrative review data collection and evaluation were limited, as only one reviewer
was the primary project leader, increasing the risk for bias and internal validity (Toronto &
Remington, 2020). For example, bias could be evidenced in the project leader's positive
evaluation of evidence that supports the integrative review hypothesis and negative assessment
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of the evidence that does not support the integrative review hypothesis (Whittemore & Knafl,
2005). In locating relevant studies for the integrative review, the project leader may include
arbitrary search limiters, such as the geographical location or year of publication which can
produce a biased sample because it might exclude a relevant body of evidence. Moreover, the
project leader may limit their literature search to databases known to them or not fully include a
representation of available databases.
Appraisal Tools
The data appraisal stage involved the development of a level of evidence matrix, which
entailed the ordering, categorization, and summarization of data found in the literature selected.
The process entailed collecting data that coincided with the review's focus, which was palliative
care for patients with end-stage renal disease. The records of this analysis process are kept for
integrity and transparency purposes. The level of evidence matrix entailed collecting and
recording the citations, examining each source, and analyzing the purpose of the integrative
review. The methodology used were relevant for this integrative review . According to
Whittemore and Knafl (2005), this approach allows data collected from different studies with
multiple methodologies. Additionally, this review adopted a quantitative approach that entailed
analyzing the resulting themes within the results and is presented in a table format (see Table 1).
Applicability of Results
Applicability of results (also called external validity or generalization) contains a
multidimensional concept, depending on the extent to which participants, the context of care, and
the interventions (and comparators) evaluated in studies are representative of, or can be
reproduced (Toronto & Remington, 2020). As a result, the applicability of a trial’s results could
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be limited if patients represent only a small portion of those being treated in normal practice. In
ensuring the applicability of the results, this integrative review utilized inclusion and exclusion
criteria in identifying the sources used to generate data. The research studies included those
published between 2015 and 2021, resulting in the most current literature for the topic of the
integrative review. The section was also limited to peer-reviewed journals addressing the topic of
palliative care, symptom management, and improvement of quality of life in patients with endstage renal disease. These measures ensured the applicability of the results across a larger
population.
Reporting Guidelines
According to Li et al. (2019), the purpose of an integrative review is to provide an answer
for a phenomenon or clinical question. A well-developed and written integrative review
addresses a clinical question to improve clinical practice and, or, change clinical policies, which
can impact patient care (Whittemore & Knafl 2005). Consequently, unlike other studies, an
integrative review allows for a diverse methodology that plays a more significant role in
evidence-based practice for nursing practice changes. Results from the integrative review are
displayed in a Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)
diagram (see Figure 1) to increase quality, transparency, and reporting, which would allow for
ease of viewing, interpretation, and comprehension by readers (Toronto & Remington 2020).

SECTION FIVE: DATA ANALYSIS AND SYNTHESIS

A Thematic Analysis
The data appraisal stage involved the development of a level of evidence matrix, which
entailed the ordering, categorization, and summarization of data found in the literature selected.
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The data collection focused on research studies regarding the quality of life in patients with endstage renal disease undergoing palliative care. Additionally, these research articles will be kept for
24 months for integrity purposes. The development of the level of evidence matrix involved
collecting and recording the citation and analysis focus for each source, analyzing the purpose of
the integrative review, the methodology used, its limitations, and its relevance for this integrative
review. This approach allowed the project leader to collect data from different studies with
multiple methodologies. This review adopted a quantitative approach that entailed analyzing the
resulting themes within the results. The results are presented in a table format (see Table 1 for the
results of matrix) (Toronto & Remington, 2020; Whittemore & Knafl, 2005).
The literature review revealed several positive factors about applying palliative care in
patients with end-stage renal disease. The study review process identified themes that supported
the topic of palliative care on quality of life in patients with end-stage renal disease. The process
involved the development of the leveling of the evidence matrix that entailed the ordering,
categorization, and summarization of data found in the studies selected. According to
Whittemore and Knafl (2005), this approach allows for the project leader to collect data from
different studies with multiple methodologies and organize and data to support the topic of
interest. Overall, the literature review results reinforce the need for palliative care incorporation
in the care of patients with end-stage renal disease, which will lead to an improvement in their
overall quality of life. The summary is presented in Table 1 below.
Descriptive Results
The data identified while conducting research for this integrative review included themes
related to factors that affected the care of the patients with end-stage renal disease and their
improved quality of life. The information extracted from the literature search included outlines
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and themes, building a link to help synthesize the results in such a way to help the reader to
understand better the data (Whittemore & Knafl, 2005).
The themes which were extracted from the literature review are assessment tools
identifying symptoms to improve quality of life in patients with end-stage renal disease, current
barriers limiting palliative care consults, current practice related to symptoms assessment and
management prior to palliative care, and lastly, the effectiveness of palliative care in the
management of patients with end-stage renal disease.
Synthesis
The project leader reflected on a possible correlation between palliative care and
improved quality of life in patients with end-stage renal disease. This is further explored under
the four themes identified in the literature review and mentioned in the preceding paragraph.
Current Barriers Limiting Palliative Care Consult
The barriers limiting the application and effectiveness of palliative care by medical
providers (especially nephrologists) other than palliative care providers were discussed in 11 of
the 30 studies selected for this integrative review Alshamsi et al., 2018; Axelsson et al., 2019;
Bates et al., 2017; Castro, 2019; Davis et al., 2015; Hawley, 2017; Jablonski, 2007; Jawed et al.,
2019; Lazenby et al., 2017; Pommer et al., 2019; Sturgill & Bear, 2019. The research articles
identified barriers, such as lack of training received by providers when discussing renal disease
prognosis during end-stage renal disease, as well as providers not fully understanding the role of
palliative care and how they can be of benefit in the care of patients with end-stage renal disease
in active treatment. Additionally, nephrologists expressed fear related to the belief that involving
palliative care will result in the premature withdrawal of hemodialysis from their patients.
Alshamsi et al. (2018) concluded that 83% of the nephrologists in the literature continued to
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provide dialysis to patients in a vegetative state due to this belief, and 48% of nephrologists
reported that they would not withhold hemodialysis for patients who develop kidney failure to
avoid having difficult discussions related to discontinuing treatment.
Axelsson et al. (2019) also identified challenges that limited the improvement of the
patient’s quality-of life related to the coordination of care of the end-stage renal patient, which
included communication issues between the patient’s hemodialysis setting as well as providers,
which can have a negative effect on the patient’s quality of life. Barriers also identified were
based on the provider’s experience with palliative care, beliefs, and knowledge, as these showed
to be critical predictors of who will place palliative care consults which can affect the
management of patient care and lead to poor quality of life. Such decisions are influenced by
socio-cultural and religious beliefs, and hospital policies which can limit the use of palliative
care for patients with end-stage renal disease, thus impacting the patients’ quality of life. Jawed
et al. (2019) noted that some barriers to palliative care in current practice include the lack of
awareness of the palliative care option, symptom management needs of end-stage renal patients,
time constraints of office visits, and inadequate patient assessments as well as the emphasis
placed on hospital discharges.
Bates et al. (2017) explained that most patients have financial challenges that limit their
access to care and treatment options for a better quality of life. The respondents of the study cited
the change of roles from breadwinner to dependent as a significant psychological issue
preventing them from seeking palliative care. Sturgill & Bear (2019) stated that there are clinical
tools for clinicians to accurately prognosticate patients that will assist in making decisions
regarding palliative care needs. Similar to the findings by Bates et al. (2017), most patients with
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end-stage renal disease are less likely to utilize the palliative care benefit due to fears that their
symptom burden needs would not be addressed. Thus, their quality of life will not be improved.
Lazenby et al. (2017) revealed that physicians avoid prognosis discussions with patients
as they are under the assumption that patients do not want to discuss the prognosis. The literature
review shows that by avoiding these discussions, these physicians are unknowingly limiting their
patients’ capacity to make informed decisions affecting their care, thus impacting their quality of
life and their right to choose. Furthermore, the literature shows that advanced care planning is
not commonly carried out, and end‐of‐life care discussions are seldom initiated before patient
deterioration. The literature also showed that there is variability in the quality of life practices at
end‐of‐life amongst nephrologists; some patients are felt to be withdrawn from dialysis too late,
thus leading to poorer quality of life toward the end of life. Additionally, the options of
withholding or withdrawal from hemodialysis are not commonly discussed with patients and/or
families. Thus, when these treatments are discontinued, patients carry a heavy symptom burden
which can have a negative impact on their quality of life toward the end of life. Castro (2019)
revealed the factors that limit access to palliative care includes patients’ age, increased
comorbidity associated with end-stage renal disease, and patients’ socioeconomic status.
Furthermore, patients with end-stage renal disease should be managed by a nephrologist, and for
symptom management, they should be managed by a palliative care specialist for improved
symptom management and better quality of life outcomes.
Pommer et al. (2019) explained that physicians were not familiar with the utilization of
palliative care services while patients were actively undergoing hemodialysis treatment.
Moreover, palliative care was only utilized by patients undergoing conservative renal care, and
when providers felt that their patients’ condition was presumed fatal or had poor mental and
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physical conditions, and hemodialysis would be contraindicated for survival. Patients only
received a palliative care consult from the nephrologists when the end of life was near or when
patients were ready for the withdrawal of hemodialysis—which led to late palliative care
consults and heavy symptom burden towards end-of-life. Davis et al. (2015) stated that late
palliative care consults decrease the benefits to patients and their families, which may be due to
the team's lack of education in palliative care services or lack of resources and staff in the
institution that provides palliative care services.
Hawley’s (2017) study suggested that barriers preventing palliative care consults are
ignorance regarding palliative care, reluctance to refer to the service, not fully understanding the
positive resources of palliative care. Lastly, the fear of upsetting patients when the term
“palliative care” is used, fearing that patients may confuse the word “palliative care” and
“hospice” as being the same. The study also stated that providers did not want to turn their
patients over to palliative care, fearing that the patient may feel that they were abandoning them
to another service or the fear that their patients may see a palliative care referral as an admission
of failure to cure or treat them.
This section concluded that providers should be educated on their ability to identify
patients with end-stage renal disease symptom burden and the impact of those symptoms on their
patients’ quality of life. Nephrologists should be required to have the training to assess and treat
the symptom burden that accompanies patients with end-stage renal disease, which may include
pain, fatigue, muscle cramps, and nausea, among others. Additionally, for those nephrologists
who are not appropriately trained or feel competent with managing these symptoms, referrals to
palliative care for symptom management should be given, affording patients better access to
improved symptom burden and a better quality of life.
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Current Practice Related to Symptoms Assessment and Management Prior to Palliative Care.
Patients with end-stage renal disease have a significant symptom burden that most
nephrologists fail to assess. Due to the failure to assess patients’ symptom burden, patients suffer
poorer quality of life during their disease trajectory, leading to increased symptom burden and
recurrent hospitalization. These studies address the nature of these symptom burdens and how
nephrologists make decisions regarding end-stage renal disease symptom management. The
nature of the care provided to patients on hemodialysis related to symptom burden prior to
palliative care was discussed in seven of the 30 selected studies. These studies include Alshamsi
et al. (2018); Bates et al. (2017); Grubbs et al. (2017); Kwok et al. (2016); Jawed et al. (2019);
Lowney et al. (2015); and Pommer et al. (2019).
Alshamsi et al. (2018) suggested that the decision-making of some nephrologists was
influenced by factors such as socio-cultural beliefs, hospital policies, and religious beliefs
regarding symptom assessment and symptom management, causing a lack of care toward
patients with end-stage renal disease. The study by Kwok et al. (2016) revealed that the five most
prevalent symptoms for end-stage renal disease patients were dyspnea (63.7%), fatigue (51.8%),
edema (48.2%), pain (44.2%), and anorexia (38.1%). These symptoms were ascertained from
study reviews as the most troublesome symptoms experienced by patients with end-stage renal
disease. In addition, studies showed that these symptoms were poorly assessed and poorly
managed by providers if palliative care was not involved in patients’ care with renal disease. The
five most prevalent interventions initiated by nephrologists in the treatment of patients with endstage renal disease were oxygen administration (69.5%), parenteral infusion (67.3%), antibiotics
(53.5%), bladder catheterization (44.7%), and analgesic (39.8%) in the last two weeks of life.
Lowney et al. (2015) reported that since nephrologists have unique relationships with
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their patients for an extended period, they should be skilled with the basic symptom assessment
and management skills to treat the complex needs of patient refractory symptoms properly.
Nephrologists should require the basic assessment skills to meet the multifaceted needs to care
for their patients’ baseline disease symptom needs. From the literature review, the most common
causes of death for patients with end-stage renal disease were cardiovascular events (18.6%) and
infection (17.2%), which carry a high symptom burden. Thus, there is an increased need for a
nephrologist to be competent in their ability to assess for symptom burden in their patients, as
well as have the ability to manage these symptoms throughout the disease trajectory to improve
their patients’ quality of life.
Bates et al. (2017) concluded that patients with end-stage renal disease complained of
functional changes such as increased pain, insomnia, breathlessness, itching, fatigue, nausea,
vomiting, and depression. The problem occurs when patients’ symptom burdens go unassessed
and untreated for years by their nephrologists. Jawed et al. (2019) states that reduced provider
awareness of symptom assessment and management contributes to undertreatment. Research
results suggest that nephrologists’ current management approaches fail to identify patients with
end-stage renal disease symptom burden, which leads to inadequately managed symptoms
resulting in the undue suffering of patients. Further, Grubbs et al. (2017) research revealed that
patients with end-stage renal disease, compared to other illnesses with similar Palliative
Performance Scale (PPS), also reported moderate to severe anxiety and nausea. Based on those
studies, a need for palliative care teams to manage patient symptom burden, especially patients
with end-stage renal disease, is indicated. Palliative care will not only assess patient symptom
burden. Still, it will also provide providers with the education and tools needed to be adequately
trained and experienced to manage patient symptoms and distress on all levels. Symptoms may
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include physical, emotional, and existential stressors. The study also showed that symptoms
improved after consultation with palliative care providers.
The study written by Pommer et al. (2019) reported that physicians’ decisions related to
lack of symptom assessment were influenced by presumed fatal prognosis and poor mental and
physical conditions of patients, thus leading to poor management. Lack of assessment of
symptoms were left undone until patients were at end-of-life. Patients were not given any
prognostication or direction of care to help them with decision-making until they were days away
from end-of-life when they were referred to hospice care. Unfortunately, when patients were
referred to hospice, they were already suffering from a heavy symptom burden.
This section reported that providers poorly assessed symptom assessment and
management in patients with end-stage renal disease due to multiple factors. This section
suggested that assessment tools, provider training, and palliative care were highly recommended
to help improve the symptom burden and quality of life of patients with end-stage renal disease.
The Effectiveness of Palliative Care in the Management of Patients with End-Stage Renal
Disease
While conducting the literature search for this integrative review, the data indicated that
palliative care would be beneficial in the care of patients with end-stage renal disease to achieve
an improved quality of life. These studies include Bates et al. (2017); Bonner et al. (2018); Davis
et al. (2015); Gaertner et al. (2017); Grubbs et al. (2017); Jablonski (2007); Jawed et al. (2019);
Kavalieratos et al. (2016); Lowney et al. (2015); Phongtankuel et al. (2016); Quinn et al. (2020);
Rosansky et al. (2017); Siouta et al. (2016); Song et al. (2018); and Spilsbury & Rosenwax
(2017). Thus, 15 of the 30 studies addressed the effectiveness of palliative care in patients with
end-stage renal disease management.
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The study by Bates et al. (2017) reveals that symptom burdens experienced by patients
with end-stage renal disease could be better addressed through the use of a patient-centered
palliative care team. Bonner et al. (2018) reported that palliative care was highly beneficial in the
management of patients’ symptoms and its impact on improving patients’ quality of life.
Additionally, this study concluded that patients’ quality of life would be immensely enhanced
throughout the disease process when symptoms are identified and appropriately treated. Other
studies revealed that the advantage of palliative care is valuable to patients’ physical, emotional,
and social well-being and thus has a positive impact on patients’ quality of life (Davis et al.
(2015); Gaertner et al. (2017).
In addition, Grubbs et al. (2017) suggested that there are positive effects for those who
receive palliative care during treatment for their end-stage renal disease, and this research study
also helped illustrate the need for improved symptom management, which may lead to an
improved quality of life for patients with end-stage renal disease. Jablonski (2007) described that
palliative care should be offered to all patients undergoing renal replacement therapy due to
patients’ high symptom burden. As a result of this burden, these patients would benefit from
palliative care management throughout their disease process.
Jawed et al. (2019) revealed that palliative care providers are skilled in symptom
assessment and managing end-stage renal disease patients. In contrast, non-palliative providers
may not have similar training to provide these patients with the same level of care. Kavalieratos
et al. (2016) concluded that palliative care interventions were associated with improvements in
patient quality of life and symptom burden when introduced in patients with a life-limiting
illness. The study by Lowney et al. (2015) supports those patients with end-stage renal disease
do suffer from a high symptom burden and will benefit from the integration of palliative care as
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part of their supportive medical management. Finally, Phongtankuel et al. (2016) reported that
the integration of palliative care positively impacts patient quality of life.
Quinn et al. (2020) revealed that patients with end-stage renal disease who receive
palliative care interventions had associated lower symptom burden, lower hospitalizations, and
fewer emergency room visits; thus, they experience significant improvements in quality of life.
Additionally, Song et al. (2018) explained that patients reported an overall improvement in
cognitive functioning, emotional well-being, and spiritual well-being over time with
incorporating palliative care interventions. In addition to benefitting the patient physically and
emotionally, Spilsbury & Rosenwax (2017) explained that community-based palliative care
providers help to reduce healthcare costs spending by 27% per patient per day and was
associated with a reduction in the average inpatient hospital costs of nine percent per hospitalized
patient, per day.
Assessment Tools Identifying Symptoms to Improve Quality of life in Patients with End-Stage
Renal Disease
The need for effective assessment tools to identify patients’ symptom burden to manage
and treat patients properly was discussed in nine of the 30 of the selected studies Bonner et al.,
2018; Davis & Hui, 2017; Gaertner et al., 2017; Jablonski, 2017; Kavalieratos et al., 2016;
Lowney et al., 2015; Ng et al., 2021; Raj et al., 2018; Song et al., 2018. In general, the research
studies addressed the need for adequate recognition and treatment of symptom management to
improve quality of life, with the initial step being assessing patients’ symptoms. In addition, the
studies addressed a lack of standardized assessment tools for the patient with end-stage renal
disease, which addresses their physical, psychosocial, and existential symptom burden.
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Bonner et al. (2018) revealed that using an assessment tool is essential and beneficial to
track a patient’s symptom burden and quality of life toward the last year of life. The study
reviewed five different tools in patient care. These include the Australian Karnofsky
Performance Scale (AKPS), the Functional Assessment of Chronic Illness Therapy Palliative-14
(FACIT PAL-14), the Assessment of Quality of Life 6 Dimensions (AQoL-6D), the Sheffield
Profile for Assessment and Referral for Care (SPARC), and the Chronic Kidney DiseaseSymptom Burden Index (CKD-SBI). After implementing the assessment tools, nephrologists
were better able to identify patients’ symptom burden, which led to better treatment and
improved quality of life. Bonner et al. (2018) also determined that for the patient with end-stage
renal disease, a symptom assessment tool should be a part of their routine care and a routine
palliative care consult. The study concluded that with an assessment tool, physicians were able to
evaluate patient symptoms experienced and assess physical factors that impacted their quality of
life. By this assessment, providers are better able to treat their patients, resulting in an improved
quality of life. In addition, Kavalieratos et al. (2016) also utilized the Functional Assessment of
Chronic Illness Therapy Palliative (FACIT PAL), as well as the Edmonton Symptom
Assessment Scale (ESAS) to evaluate the effects of assessment tools on patients’ symptom
burden and quality of life. Research suggests that there was a steady improvement in symptom
burden and a positive reported improvement in patients’ quality of life associated with the use of
the symptom assessment tool and the integration of palliative care.
Davis and Hui (2017) explained that palliative care aims to enhance patients’ quality of
life who suffer from chronic diseases. This study focuses on patients with end-stage renal disease
and using assessment tools to assess their quality of life with the help of self-assessment
questionnaires. These authors reviewed the use of the McGill Quality of life Questionnaire, the
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EORTC-QLO-C30, and the ED-5D to assess patients with end-stage renal disease and their
responses related to the quality of life. The study suggests that palliative care assessment tools
are valuable in engaging patients when used, as they relate to the patients and improve their
quality of life throughout their disease process.
Gaertner et al. (2017) conducted a systematic review and meta-analysis to assess the
effectiveness of palliative care assessment tools in measuring the quality of life. The evaluation
tools used for this research study were the EORTC QLQ-C3 which assessed functional status and
quality of life in patients with end-stage renal disease, and the Multidimensional Quality of life
Scale (MQOLS). These questionnaires identified the need for further development of clinical
tools for symptom management and early palliative care integration in patient care. In addition,
the authors noted that both palliative care and assessment tools are best used early on in patients’
disease processes to achieve the best possible outcomes to better address patients unmet needs.
Jablonski (2017) states that palliative care is a total program designed to care for patients
with chronic diseases (such as end-stage renal disease) to improve their quality of life. This
research study investigated the use of a disease-specific assessment tool such as the
Multidimensional Symptom Assessment Scale (MSAS), which assessed the intensity, frequency,
duration, and distress associated with physical symptoms commonly experienced by patients
with end-stage renal disease. The study suggested those patients with end-stage disease
experience a high symptom burden both physically and psychologically. Those patients who
scored higher had an increased symptom burden and reported lower quality of life. The research
reflected that patients’ appreciated being allowed to express themselves to the clinician, who was
willing to listen to their otherwise neglected symptom burden. As a result, the study supports the
integration of palliative care in patients with end-stage renal disease for the best patient

PALLIATIVE CARE AND END-STAGE RENAL DISEASE

31

outcomes. For this population, it will be a managed symptom burden and improved quality of
life.
A study conducted by Lowney et al. (2015) revealed that patients who have long-term
relationships with their nephrologist had poor symptom management. Subsequently, due to these
long relationships, nephrologists might overlook components of patient care at times, which may
lead to increased symptom burden and decreased quality of life. Therefore, the authors used the
assessment tool, the Palliative Care Outcome Scale (POS-renal), from the original POS and
adapted it to meet the need of renal patients to help identify the symptom burden. The aim of the
tool was to aid nephrologists in evaluating the severity of patient symptom burden. The
completed surveys revealed that patients with end-stage renal disease had an increased frequency
and severity of symptom burden and poorer quality of life. The authors also concluded that a
multi-professional team approach is the best way to improve patient care and quality of life due
to the patient population vulnerability.
Ng et al. (2021) conducted a research study that examined the factors that impact the
symptom burden of patients with end-stage renal disease. Patients with end-stage renal disease
on hemodialysis experience significant symptom burden and, due to those symptoms, may suffer
a poorer quality of life. Identifying these factors may improve their quality of life. The tool that
was used to assess symptom burden for this study was the Dialysis Symptom Index (DSI). The
Dialysis Symptom Index assessed for the occurrences of distress from patients’ physical,
psychosocial, and sexual aspects of their life over a four-week period. The survey that was
conducted showed that 46% of the 271 participants that took part in the study scored 30% or
greater, which meant that they were experiencing a heavy symptom burden and poor quality of
life. The higher the distress score, the poorer the quality of life. The authors concluded that, due
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to the needs of the patient with end-stage renal disease, they require a holistic approach to
symptom management for an improved quality of life.
The study written by Raj et al. (2018) stated that assessment tools are valid, reliable, and
even necessary to capture patients’ subjective symptom complaints to treat them appropriately.
The assessment tool reviewed by this study was the Integrative Palliative Outcome Score Renal
(IPOS) survey, which was developed from other pre-existing assessment tools. This assessment
evaluated patients with end-stage renal disease and their views on quality of life in different
domains. As noted in the study, assessment tools help minimize patients’ hesitancy in
mentioning their symptoms to their provider and assist providers to better assess patient
symptom burden; thus, improving management and patients’ quality of life.
The research written by Song et al. (2018) discusses the results of patients’ quality of life
from an overall symptom burden standpoint. The study reviewed several assessment tools,
including the Edmonton Symptom Assessment System (ESAS), which measures overall
symptoms (e.g., pain; fatigue; insomnia; and nausea). The Center for Epidemiologic Studies
Depression Scale-Short Form (CESD-SF) measures emotional well-being, and the 12-item
Functional Assessment of Chrome (FACT-Sp) measured spiritual well-being. The studies
identified the need for patient assessment tools to evaluate symptom burden and quality of life.
Unfortunately, both are subjective and can only be known by patient self-report. Nevertheless,
the tools used were able to identify patients’ symptom burden on the different domains over 12
months. Consistently, the continued use of the assessment tools revealed improvement in
patients’ reported quality of life.
End-stage renal disease is an illness that affects more than just the kidneys. It also affects
the entire body on several different levels. In addition, patients with end-stage renal disease
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manage many other health components that affect their physical and psychosocial being (Ng et
al. 2021). It takes providers with a unique set of skills who can adequately assess, manage, and
continuously treat patients with end-stage renal disease throughout their disease trajectory to
meet their symptom management care goals. The evidence-based studies for this integrative
review recommend that palliative care be woven into routine care for patients with end-stage
renal disease to improve patients’ symptom burden and quality of life throughout the disease
process.
Ethical Considerations
This project is an integrative review that did not have human participants and did not
contain personal patient information. This integrative review complied with the Liberty
University Institutional Review Board (IRB) policies, and data was collected, analyzed, and
stored in the project leader’s computer, which is password-secured. A copy of both the
Collaborative Institutional Training Initiative (CITI) certificate and IRB approval letters are
provided in the Appendices (see Appendices A and B).
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SECTION SIX: DISCUSSION

Implications of Practice/ Future Work
The purpose of the Doctor of Nursing Practice degree serves to prepare the advanced
practice nurse to conduct research activities that will improve healthcare practice and advance
the practice of nursing. This degree plays a crucial role in implementing palliative care in caring
for patients with end-stage disease processes by enhancing the practice of nursing through
continued research and advanced practice (Edwards et al., 2018). The project leader has
conducted a rigorous literature review that has identified themes that both impact and improve
patients’ care and the quality of life of patients with end-stage renal disease. The goal of this
project was to explore the benefit of integrating palliative care for patients with end-stage renal
disease to improve their overall quality of life, including physical, mental, and psychosocial
health, and answer the question: Does palliative medicine improve the quality of life in patients
with end-stage renal disease?
A review of the literature suggests that the incorporation of palliative care for every
patient diagnosed with end-stage renal disease requiring renal replacement therapy which will
require a potential practice change may help improve symptom management for patients with
end-stage renal disease. Subsequent findings from this integrative review suggest that using a of
a symptom assessment tool would improve patient quality of life with end-stage renal disease.
Further research would need to develop and use a symptom assessment tool for patients with
end-stage renal disease, as the literature review concluded that using a symptom assessment tool
for patients with end-stage renal disease might help improve the quality of life by adequately
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identifying symptoms. However, further research would need to be done in this area, as this was
not the focus of this integrative review. Further research is also necessary to assess the ongoing
impact of assessment tools in the care of patients with end-stage renal disease and their
implications for patient care, mainly when used by nephrologists. Nevertheless, from the
literature review, the assessment tool may be an effective tool to identify patient distress to treat
sooner, improve symptom management, and improve their quality of life.
Dissemination
The findings from this integrative review will be disseminated to healthcare providers via
PowerPoint presentation and as a poster presentation. The results will be shared with the
palliative care department during Fellow Education week for the Georgia Medical Educational
Department and the Georgia Kidney Association. This presentation will reflect the evidence
from the literature of the positive impact that palliative care has on the quality of life in the
patients with end-stage renal disease. The poster will also be presented at the American
Academy of Hospice and Palliative Medicine (AAHPM) on February 9-12, 2022, in Nashville,
TN.
Summary
End-stage renal disease carries a high symptom burden for patients who are affected by
this disease. This integrative review aimed to explore whether the integration of palliative care
improves the quality of life in those patients with end-stage renal disease. While palliative care
provides an ideal opportunity to assess the wellness factors associated with end-stage renal
disease, this integrative review was conducted to explore whether palliative care improves
symptom burden in patients with end-stage renal disease, thus improving their quality of life.
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The project leader has shown the correlation between improved quality of life by showing the
four themes which are beneficial to the care of the patient with end-stage renal disease and how
palliative medicine can positively impact patient care.
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d
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palliative
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(9% of the
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Yes. The findings will
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the need to train
nephrologists and
physicians in palliative
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care. Expert Review of
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To provide an
updated synopsis
on the use of
quality of life
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analysis
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Questionnaire
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had a
palliative
care-related
hospitalizatio
n.
Several
Level
quality of life I
questionnaire
s have been
validated
useful in
palliative
care settings.
However
there still are
several gaps
that impede
their use in
the clinical
setting.

This study was
not specific to a
patient with
end-stage renal
disease.

Yes, this study could
be adapted to focus on
patients with end-stage
renal disease and on
the palliative care
setting; we will define
quality of life, discuss
how quality of life
instruments can be
used clinically and in
research, review
approaches to validate
these questionnaires,
and how they can be
used in utility
analyses.
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Davis, M., P., Temel, J., S.,
Balboni, T., & Glare, P.
(2015). A review of the
trails which examine early
integration of outpatient
and home palliative care
for patients with serious
illness. Annals of Palliative
Medicine; 4(3), 99-121.
https://
doi.org/10.3978/j.issn.2224
-5820.2015.04.04

The integrative
review sought to
investigate the
benefits of early
palliative care in
the course of the
disease trajectory
for patients with
serious illnesses as
an outpatient and
at
home.

The literature
search yielded
15 randomized
control trials
of outpatient
palliative care
and 13
randomized
control
trials of
palliative home
care. It also
included 7
systematic
reviews. These
were collated
into
tables.
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The
methodolo
gy
entailed a
systematic
review of
palliative
care
randomize
d control
trials.

The
Level
integrative
1
review
revealed
advantages
such as
improvement
in symptoms
such as
depression,
improved
patient
quality of
life, reduced
aggressive
care at the
end of life,
increased
advanced
directives,
reduced
hospital
length of stay
and
hospitalizatio
ns, improved
caregiver
burden and
better
maintenance
of
caregiver
quality of life

The integrative
review failed to
identify what is
meant by
“early”
palliative care.

Yes. The integrative
review demonstrates
the benefits of
palliative medicine. It
is useful to the DNP
project and proves the
need to provide
palliative medicine
consult in the care of
ARD patients.
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Eckert, K., Motemaden, L., &
Alves, M. (2018). Effect of
hemodialysis compared
with conservative
management on quality of
life in older adults with
end-stage renal disease.
Journal of Hospice &
Palliative Nursing, 20(3),

How does
palliative care
improve quality of
life in patients
with advanced
renal disease?

N=110-441.
Systemati
Studies
c review
conducted over
a 2–3-year
period. Patient
with
glomerular
filtration rate
(GFR) less
than 15.
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and reduction
in the
medical cost
of care, as
well as
patient and
family
satisfaction.
Some of the
reviewed
studies
showed that
symptoms
and quality
of life are not
improved,
and
resource
utilization
and costs are
not different
from “usual”
care.
Discusses
Level
that patients
II
who choose
forgo
hemodialysis
may
experience a
better quality
of life than
those who

There was
limited research
on quality of
life to guide this
research related
to hemodialysis

This study would help
to build the that
patients with advance
renal disease do suffer
from a higher
symptom burdens and
those symptoms will
in fact impact patient’s
quality of life. Nut
when those symptoms
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https://doi.org/10.1097/njh.000000
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Gaertner, J., Siemens, W.,
Meerpohl, J. J., Antes, G.,
Meffert, C., Xander, C.,
Stock, S., Mueller, D.,
Schwarzer, G., & Becker,
G. (2017). Effect of
specialist palliative care
services on quality of life
in adults with advanced
incurable illness in
hospital, hospice, or
community settings:
Systematic review and
meta-analysis. BMJ, 357,
1-15
j2925. https://doi.org/10.11
36/bmj.j2925
Study 12
Grubbs, V., O’Riordan, D., &
Pantilat, S. (2017).
Characteristics and
outcomes of in-hospital
palliative care consultation
among patients with renal
disease versus other serious
illnesses. Clinical Journal
of the American Society of

54
choose to
undergo
hemodialysis
.

are addresses and
manages patients can
experience a better
quality of life.

To assess the
effect of palliative
in patient with
advanced illness.

N=3967
publication
were reviewed
with 10
randomized
controlled
trails with
2454 patients.

Systemati
c review
and metaanalysis

Patients’
Level
quality of life I
in all aspects
were
improved
with the
incorporation
of palliative
medicine.

Many patients
in specialized
palliative care
studies will die
before the point
in time of the
primary quality
of life analysis.

Yes, Patient’s quality
of life in all aspects
were improved with
the incorporation of
palliative medicine,
(physical, emotional,
and social).

To compare rates
of symptom
severity and
improvement and
needs for advanced
care planning
between patients
referred for
palliative care
consultation

N=33,183
patients, of
whom 1057
(3.2%) had
end-stage renal
disease.

Observati
onal study

Patients with
renal disease
or other
illnesses had
similarly low
mean
Palliative
Performance
Scale scores
and reported

Potential bias in
a patient
selection, where
researchers
concentrated on
the sickest ones,
which may not
be reflective of
the needs of the
entire

Yes. It shows the
effects of palliative
care and the
limitations that
prevent its application
to renal patients. It
will help illustrate the
need for the improved
management and

Level
IV
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because of renal
1089. https://doi.org/10.221 disease and those
5/cjn.12231116
with other serious
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Horton, J. R., Morrison, R.,
Capezuti, E., Hill, J., Lee,
E. J., & Kelley, A. S.
(2016). Impact of inpatient

Examined the
relationship
between palliative
care and average
hospital length in

N=295
hospitals with
palliative care
programs.

Observati
onal study

similar
moderate to
severe
anxiety and
nausea.
Symptoms
improved
similarly
after
consultation
regardless of
diagnosis
except for
anxiety,
which
improved
more often
among those
with renal
disease.
Fewer
patients with
renal disease
were referred
to hospice
than those
with other
illnesses.
Patient
palliative
care program
alone not
sufficient to

Level
V

hospitalized
ESRD
population

improved quality of
life.

Patient
palliative care
program alone
not sufficient to
impact hospital

No, this study did not
support project goal of
proving improving
quality of life,
decreased
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relation to
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of life.
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Jablonski, A. (2007). Level of
symptom relief and the
need for palliative care in
the hemodialysis
population. Journal of
Hospice & Palliative
Nursing, 9(1), 50–
58. https://doi.org/10.1097/
00129191-20070100000010

The purpose of
this study was to
document the level
of symptom relief
of patients with
end-stage renal
disease treated
with hemodialysis
when they were
treated by the
palliative care
services and the
impact on their
quality of life.
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Jawed, A., Moe, S., Moorthi, R.,
Torke, A., & Eadon, M.
(2019). Increasing
nephrologist awareness of
symptom burden in older
hospitalized end-stage

Improve the
nephrologist
awareness of
symptom leads to
symptom
improvement, thus

impact
hospital
length of stay
nor did it
impact
patient
perceived
quality of
life.
N= Two inDescriptiv The study
center dialysis e crossconcluded
clinics located sectional
that with the
in the Midwest design
incorporation
US. The
of palliative
census of 281
care, patients
patients.
showed
51% male
improvement
49% female.
in symptom
management
and thus
showed an
overall
improvement
in their
quality of
life.
N= 52 patients, Prospectiv Improve the
with one who
e
nephrologist
passed during
multicente awareness of
the study.
red
symptoms
interventio leads to
nal study
symptom
improvement
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perceived
quality of life.

hospitalization, or
decreased symptom
burden.

Level
V

The
measurement
tool used to
measure
symptoms and
level of relief as
acknowledged,
which was a
disease-specific
tool that
assesses all
symptoms and
was not specific
to those of renal
disease only.

Yes, this paper
concluded that
palliative care should
be offered to patients
undergoing renal
replacement therapy
due to their high
symptom burden. And
due to their high
symptom burden
would benefit from
palliative care
management.

Level
IV

The limitations
small sample
size2nd
Positions were
aware that the
study was taken

Yes, this study proved
that without palliative
care management,
other providers are not
skilled and are
inadequate in the
management of
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renal disease
patients. American Journal
of Nephrology, 51(1), 1116. https://doi.org/10.115
9/000504333
Study 16
Kavalieratos, D., Corbelli, J.,
Zhang, D., Dionne-Odom,
J., Ernecoff, N. C.,
Hanmer, J., Hoydich, Z. P.,
Ikejiani, D. Z., KleinFedyshin, M.,
Zimmermann, C., Morton,
S. C., Arnold, R. M.,
Heller, L., & Schenker, Y.
(2016). Association
between palliative care and
patient and caregiver
outcomes. JAMA, 316(20),
2104–
2114. https://doi.org/10.10
01/jama.2016.16840
Study 17
Kwok, A. O., Yuen, S., Yong, D.
S., & Tse, D. M. (2016).
The symptoms prevalence,
medical interventions, and
health care service needs
for patients with end-stage
renal disease in a renal
palliative care
program. American
Journal of Hospice and

57

improved quality
of life.

, thus an
improved
quality of
life.

place
randomized.

symptom in patent
with end-stage renal
disease.

To determine the
association of
palliative care with
quality of life
symptom burden,
survival, and other
outcomes for
people with lifelimiting illness.

N= 43
Randomized
controlled trial
provided data
on 12,731
patients.

Systemati
c review
and Metaanalysis.

Palliative
care was
associated
with
improvement
s in quality
of life and
symptom
burden, but
not with
improved
survival.

Level
1

The study
limitations
included what
the author listed
as missing data
that could not
be included
after contacting
authors such as
quasiexperimental
studies, several
of which have
demonstrated
benefits of
palliative care.

Yes; this study
concluded that
palliative care
interventions were
associated with
improvements in
patient quality of life
and symptom burden.

Evaluated the
prevalence of
symptoms and
interventions
initiated in the last
two weeks of life,
health care service
utilization, and
causes of death of
patients with endstage renal disease

N= 335 endstage renal
patients.

A
retrospecti
ve study

The 5 most
Level
prevalent
IV
symptoms
were dyspnea
(63.7%),
fatigue
(51.8%),
edema
(48.2%), pain
(44.2%), and

The study was
conducted in
one center,
which posed the
limitation of
generalization
of the results.
The response
rate on the
satisfaction
survey was only

This study revealed
the symptom burdens
that end-stage renal
disease patients
experience and how
they could be
addressed through the
provision of patientcentered palliative
care.
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Palliative
Medicine®, 33(10), 952–
958. https://doi.org/10.117
7/1049909115598930

(ESRD under renal
palliative care
(RPC) program.
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anorexia
(38.1%).
The five
most
prevalent
interventions
initiated were
oxygen
(69.5%),
parenteral
infusion
(67.3%),
antibiotics
(53.5%),
bladder
catheterizatio
n (44.7%),
and analgesic
(39.8%) in
the last two
weeks of life.
Each patient
received 3.5
± 4.4
outpatient
clinic visits,
3.4 ± 10.3
home care
visits, and
3.1 ± 2.7
hospital
admissions.

around 65%,
which may not
be able to
represent all
bereaved
patients’
families.
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Study 18
Lazenby, S., Edwards, A.,
Samuriwo, R., Riley, S.,
Murray, M., & CarsonStevens, A. (2016). Endof-life care decisions for
hemodialysis patients - ‘we
only tend to have that
discussion with them when
they start
deteriorating’. Health
Expectations, 20(2), 260–
273. https://doi.org/10.111
1/hex.12454

Identified the
experiences and
perceptions of
doctors and nurses
in nephrology for
involving
hemodialysis
patients in end‐of‐
life care decisions.

N= A sample
of 15 doctors
and five
nurses in a
large teaching
hospital in
Wales, UK.
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A semi‐
structured
qualitative
interview
study

The most
common
causes of
death were
cardiovascul
ar events
(18.6%) and
infection
Doctors and
Level
nurses avoid VI
discussing
prognosis
with patients
with the
assumption
that the latter
does not
want the
information.
Advance care
planning is
rarely carried
out, and end‐
of‐life care
discussions
are seldom
initiated prior
to patient
deterioration.
There is
variability in
end‐of‐life
practices

The sample size
was small,
which limits the
generalizability
of results. The
dependence on
interviews
could have
resulted in
respondent bias.

The study provides
profound insights into
the management of
end-of-life patients’
renal care. It illustrates
the need for improved
care and new
interventions to
enhance clinical
outcomes.
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Study 19
Lowney, A. C., Myles, H. T.,
Bristowe, K., Lowney, E.
L., Shepherd, K., Murphy,
M., O'Brien, T., Casserly,
L., McQuillan, R., Plant,
W. D., Conlon, P. J.,
Vinen, C., Eustace, J. A.,

The study
N= total of 893
describes the
patients on
symptom profile of hemodialysis.
a large cohort of
patients with endstage renal disease
on hemodialysis
and evaluates how

60

Prospectiv
e Crosssectional
observatio
nal.

amongst
nephrologists
; some
patients are
felt to be
withdrawn
from dialysis
too late.
Furthermore,
the
possibility
and
implications
of
withdrawal
are not
commonly
discussed
with well
patients. End
of life care is
not delivered
well, which
limits the
quality of life
Patients with Level
end-stage
V
renal disease
have a high
symptom
burden and
experience a
poor quality

Limitations
include the
absence of
comorbidity
indices and
biochemical
data from the
analysis. A

Yes, this study
supports the fact that
patients with end-stage
renal disease do suffer
from a high symptom
burden and can and
will benefit from the
incorporation of
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& Murtagh, F. E. (2015).
Understanding what
influences the healthrelated quality of life of
hemodialysis patients: A
collaborative study in
England and
Ireland. Journal of Pain
and Symptom
Management, 50(6), 778–
785. https://doi.org/10.101
6/j.jpainsymman.2015.07.0
10
Study 20
Ng, M., Wong, C., Choi, K., Hui,
Y., Ho, E., Miaskowski,
C., & So, W. (2020). A
mixed methods study of
symptom experience in
patients with end-stage
renal disease. Nursing
Research, 70(1), 34–
43. https://doi.org/10.1097/
nnr.0000000000000479
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symptom burden
and other factors
influence quality
of life scores.

The aim of this
study was to
explore factors that
are associated with
patient symptom
experiences, using
a symptom index
to assess symptom
burden.

of life
compared to
the
population of
patients who
do not suffer
from endstage renal
disease.

N=271
participants to
examine
association of
patient
experience.

Mixed
methods
design
using
quantitativ
e and
qualitative
componen
ts

Patients with
end-stage
renal disease
receiving
next dialysis
experienced
a significant
symptom
burden.

Level
III

decision was
made not to
include these
data as
comorbidity
data, with the
exception of
diabetic status,
were not
recorded in a
standardized
format in the
medical records
in this study.
The author
noted that there
was no
difference in
symptoms
based on the
types of dialysis
received from
patients. The
second
limitation was
noted that there
was only a
limited number
of
demographics
and clinical
characteristics
evaluated based

palliative care as part
of their care.

Yes, the study was
able to conclude that
there are several
significant
associations between
patients reported
symptom burden using
correlation
coefficients and
multivariate regression
analyses.
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Study 21
Noble, H., Agus, A., Brazil, K.,
Burns, A., Goodfellow, N.
A., Guiney, M., McCourt,
F., McDowell, C.,
Normand, C., Roderick, P.,
Thompson, C., Maxwell,
A. P., & Yaqoob, M. M.
(2015). Palliative care in
chronic kidney disease:
The packs study—quality
of life, decision making,
costs and impact on carers
in people managed without
dialysis. BMC
Nephrology, 16(104), 1–
11. https://doi.org/10.1186/
s12882-015-0084-7

The study sought
to understand how
patients make
clinical care
decisions and the
impact of those
decisions on
caregivers
regarding the
application of
conservative
kidney
management.

N= 112
patients is
required.

The study
is
ongoing,
and the
study
results
have not
been
published.

A
Level
prospective
IV
multicenter,
longitudinal
study. It is a
mixedmethod study
with both
qualitative
and
quantitative
components.

Study 22
Phongtankuel, V., Meador, L.,
Adelman, R. D., Roberts, J.,
Henderson, C. R., Mehta, S.
S., del Carmen, T., & Reid,
M. (2016). Multicomponent
palliative care interventions
in advanced chronic
diseases: A systematic
review. American Journal of
Hospice and Palliative
Medicine, 35(1), 173–

To assess the
delivery of
palliative care
intervention on
patient quality of
life.

N=71 studies
which detailed
64 unique
palliative care
interventions.

Systemati
c review

The study
Level
produced 71 I
studies,
which
detailed 64
unique
multicompon
ent palliative
care
interventions.

on the review of
literature.
The study will
be based on
self-reports by
participants
who will
introduce
tendencies of
bias.

The author
listed
limitations such
as exclusions of
articles not
written in
English,
articles that
excluded
patients at end
of life study
may not reflect

The study will reveal
the needs of patients
and the effects of their
decisions on
caregivers. It will
show the importance
of new approaches to
care.

Yes, this study shows
that the integration of
palliative care has an
positive impact on
patient quality-of-life.
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183. https://doi.org/10.1177/
1049909116674669

Study 23
Pommer, W., Wagner, S., &
Thumfart, J. (2019).
Conservative care, dialysis
withdrawal, and palliative
care: Results from a survey
of a non-profit dialysis
provider in
Germany. Kidney and
Blood Pressure
Research, 44(2), 158–
169. https://doi.org/10.115
9/000498994

To understand the
practice pattern
concerning
conservative care,
dialysis
withdrawal, and
palliative care
support in renal
patients

To understand
the practice
pattern
concerning
conservative
care, dialysis
withdrawal,
and palliative
care support in
renal patients.

Randomiz
ed survey
method

Most
facilities and
physicians
were not
associated
with the
utilization of
conservative
renal care
and dialysis
withdrawal.
Palliative
care varied
between

Level
IV

palliative care
interventions
first the author
listed
comprehensive
search strategies
which were
studies
excluded which
were not written
in English and
intervention
excluded that
only targeted
patients who
were at end of
life. published
during the study
period.
The study did
not evaluate
compliance
with the
fundamentals of
palliative
medicine,
quality of
caregiving,
procedure, or
documentation
of decisionmaking process,
which might

Yes. It reveals
attitudes toward
palliative care and
barriers to effective
palliative care. The
findings will help
identify the issues that
should be addressed to
make palliative care
effective.
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64
facilities and
physicians.
Palliative
care was
only
established in
patients
undergoing
conservative
renal care
Physicians’
decisions
were
influenced by
presumed
fatal
prognosis
and poor
mental and
physical
conditions of
patients.
Provision of
palliative
care was
limited by
lack of
education in
palliative
medicine,
shortness of
staff, and
lack of

contradict the
responses
provided by the
participants.
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Study 24
Quinn, K. L., Shurrab, M., Gitau,
K., Kavalieratos, D.,
Isenberg, S. R., Stall, N.
M., Stukel, T. A.,
Goldman, R., Horn, D.,
Cram, Detsky, A. S., &
Bell, C. M. (2020).
Association of receipt of
palliative care interventions
with health care use,
quality of life, and
symptom burden among
adults with chronic
noncancer
illness. JAMA, 324(14),
1439. https://doi.org/10.10
01/jama.2020.14205
Study 25
Raj, R., Ahuja, K., Frandsen, M.,
Murtagh, F. E., & Jose, M.
(2018). Validation of the
ipos-renal symptom survey
in advanced kidney
disease: A cross-sectional
study. Journal of Pain and
Symptom
Management, 56(2), 281–
287. https://doi.org/10.101
6/j.jpainsymman.2018.04.0
06
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The effect of
palliative care on
the importance on
end-of -life
outcomes in
patients with
noncancer illness.

N= 28
Randomized
controlled trial
of patients, 8
randomized
clinical trials
of patients with
primarily
noncancer
illness.

Systemati
c review
and metaanalysis.

To assess the
validity and
reliability of the
IPOS-renal survey
(patient and staff
version).

N= 81 patients
(65
hemodialysis,
10 peritoneal
dialysis, and
six on
supportive
care; average
ages are 64.9
years).

A crosssectional
study

financial
resources.
Patients to
Level
receive
I
palliative
care
interventions
have
associated
lower
symptom
burden,
lower
hospitalizatio
n, and fewer
emergency
room visits.

The study
Level
resulted that III
the IPOS was
able to
collect the
patient
subjective
illness
concern and
symptom
burden.

The study
included several
other medical
conditions, not
just renal
diseases. Many
of the elements
of palliative
care were also
present in usual
care, which may
underestimate
the magnitude
of the findings.

Yes, in one aspect but
not related to quality
of life as this study
shows that palliative
care compared with
usual care, was
statistically
significantly
associated with less
acute health care use
and modestly lower
symptom burden, but
there was no
significant difference
in quality of life

None

Yes, very. Because
symptom burden ad
quality of life are
subjective an
assessment tool is the
best way to capture
patients’ most accurate
responses for the most
appropriate treatment..
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Rosansky, S. J., Schell, J., Shega,
J., Scherer, J., Jacobs, L.,
Couchoud, C., Crews, D.,
& McNabney, M. (2017).
Treatment decisions for
older adults with advanced
chronic kidney
disease. BMC
Nephrology, 18(200), 1–
10. https://doi.org/10.1186/
s12882-017-0617-3

To understand how
adult renal patients
make decisions
regarding dialysis
initiation.

N= patient
chart review
from 19802012

66
Observati
onal
respective
study

Older adults Level
with
VI
advanced
CKD are
likely to die
from nonrenal failure
related
conditions
before they
are faced
with a
decision
concerning
dialysis.
Most patients
who initiate
dialysis
initiate
treatment
early.
Most initiate
dialysis
because of
acute renal
failure.
Dialysis does
not provide
survival
benefits for
older adults
with poor
mobility and

None

Yes. The study shows
the need for early
palliative care and
alternative treatments
or older renal patients.
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Study 27
Siouta, N., Beek, K., V., van der
Earden, M., E., Preston, N.,
Hasselaar, J., G., Hughes,
S., Garralda, E., Centeno,
C., Csikos, A., Groot, M.,
Radbruch, L., Payne, S., &
Menten, J. (2016).
Integrated palliative care in
Europe: A qualitative
systematic literature review
of empirically tested
models in cancer and
chronic disease. BMC
Palliative Care; 15(56), 216.
https://doi.org/10.1186/s12
904-016-0130-7

To identify
empirically
evaluated
models of
palliative care
(PC) in cancer and
chronic disease in
Europe, and
develop a generic
framework that
will consist of the
basis for the
design of future
models for
integrated PC in
Europe

14 studies were
included: 7
models for
chronic
disease, 4 for
integrated care
in oncology, 2
for both
cancer and
chronic
disease, and 2
for end-of-life
pathways.

A
systematic
review of
literature
published
from 01011995 to
31-122013.

Study 28

The study
evaluated the one-

N= 227
patients

Longitudi
nal

high levels of
comorbidity.
There is a
strong
agreement on
the benefits
of the
involvement
of a
palliative
care
multidiscipli
nary team:
better
symptom
control, less
caregiver
burden,
improvement
in continuity
and
coordination
of care,
fewer
admissions,
cost
effectiveness,
and patients
dying in their
preferred
place.
Patients
reported

Level
I

The broadness
of the topic
under
investigation.

Yes. The integrative
review describes the
benefits of palliative
care and effective care
models.

Level
V

Study was
conducted in a

Yes, this study was
able to prove palliative
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Song, M.-K., Paul, S., Ward, S. E.,
Gilet, C. A., & Hladik, G.
A. (2018). One-year linear
trajectories of symptoms,
physical functioning,
cognitive functioning,
emotional well-being, and
spiritual well-being among
patients receiving
dialysis. American Journal
of Kidney Diseases, 72(2),
198–
204. https://doi.org/10.105
3/j.ajkd.2017.11.016

year trajectory of
patient reported
dimensions of
quality of life
among patients on
dialysis.

recruited from
12 dialysis
centers.

observatio
nal study

overall
symptoms,
cognitive
function,
emotional
well-being,
and spiritual
well-being
improved
over time
with the
incorporation
of palliative
care
intervention.

Study 29
Spilsbury, K., & Rosenwax, L.
(2017). Community-based
specialist palliative care is
associated with reduced
hospital costs for people
with non-cancer conditions
during the last year of
life. BMC Palliative
Care, 16(1), 1–
12. https://doi.org/10.1186/
s12904-017-0256-2

To determine if
community-based
palliative care
provided to people
dying from noncancer conditions
was associated
with reduced
hospital costs in
the last year of life
and how this
compared with
people dying from
cancer.

N= 12,764
decedents who,
combined,
spent 451,236
(9.7%) days of
the last year of
life in hospital.

A
retrospecti
ve cohort
studies.

All the
decedents
spent 451236
days of the
last days in
the hospital.
Communitybased
specialist
palliative
care reduced
their care
costs by 27%
per decedent
per day.
Communitybased

Level
IV

single region of
the US and
included mostly
patients with
high level of
function.

care positively
impacting patients’
overall quality of life,
and decreases in their
symptom burden when
employed in their care.

It is possible
residual
confounding by
indication from
the lack of
clinical detail,
particularly for
nonhospitalized
decedents, and
motivations for
accessing
communitybased specialist
palliative care.
The intensity of
palliative care

Yes. It shows the
effect of palliative
care on the cost of
healthcare, which
reinforces the need for
early palliative care.
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Sturgill, D., & Bear, A. (2019).
Unique palliative care
needs of patients with
advanced chronic kidney
disease – the scope of the
problem and several

Identified the
barriers to
effective palliative
care and solutions
to them.

N= 227
patients
recruited from
12 dialysis
centers.
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Longitudi
nal
observatio
nal study

specialist
palliative
care was also
associated
with a
reduction of
inpatient
average
hospital costs
of 9% per
hospitalized
decedent per
day.
Hospital cost
reductions
were
observed for
decedents
with organ
failures,
chronic
obstructive
pulmonary
disease, and
Alzheimer’s
disease.
There are
Level
few clinical
VI
tools
for clinicians
to accurately
prognosticate

was not
assessed

The authors
notes that they
rely on past
literature. There
is a need for
first-hand data
to confirm the

Yes. The study
illustrates the factors
that limit effective
renal care and the
needs that will better
address them, which
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solutions. Clinical
Medicine, 19(1), 26–
29. https://doi.org/10.7861/
clinmedicine.19-1-26
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for individual
patients.
Patients with
ESRD are
less likely to
utilize the
hospice
benefit than
patients with
other
terminal
illness.

validity of the
results.

will then in turn
improve patient care.

PALLIATIVE CARE AND END-STAGE RENAL DISEASE
Appendix A

71

PALLIATIVE CARE AND END-STAGE RENAL DISEASE

72

Appendix B

June 17, 2021
Natoya Bender
Brenda Jessee
Re: IRB Application - IRB-FY20-21-1033 Palliative Care and Improving Quality of life in Patients
with End Stage Renal Disease: An Integrative Review
Dear Natoya Bender and Brenda Jessee,
The Liberty University Institutional Review Board (IRB) has reviewed your application in
accordance with the Office for Human Research Protections (OHRP) and Food and Drug
Administration (FDA) regulations and finds your study does not classify as human subjects research.
This means you may begin your project with the data safeguarding methods mentioned in your IRB
application.
Decision: No Human Subjects Research
Explanation: Your study is not considered human subjects research for the following reason:
(4) “Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism,
legal research, and historical scholarship), including the collection and use of information, that focus
directly on the specific individuals about whom the information is collected,” are not considered
research according to 45 CFR 46.102(l)(1).
Please note that this decision only applies to your current application, and any modifications to your
protocol must be reported to the Liberty University IRB for verification of continued non-human
subjects research status. You may report these changes by completing a modification submission
through your Cayuse IRB account.
Also, although you are welcome to use our recruitment and consent templates, you are not required
to do so. If you choose to use our documents, please replace the word research with the
word project throughout both documents.
If you have any questions about this determination or need assistance in determining whether
possible modifications to your protocol would change your application's status, please email us
at irb@liberty.edu.
Sincerely,
G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
Research Ethics Office
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Table 2
Inclusion an Exclusion criteria applied to the literature review
Inclusion

Exclusion

Peer reviewed articles

Patients of the pediatric population

Articles written in last five years

Patient with renal disease that are
not end stage
Articles that are older that five years
old

Articles that have adult patients
diagnosed with end-stage renal
disease
Articles written in English
Patients requiring renal replacement
therapy
Patients seen in both the acute care
and outpatient setting.

Articles which are Editorials and or
new blogs
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Melnyk’s Hierarchy of Evidence
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Figure 1

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 791)

Additional records identified
through other sources
(n = 0)

Eligibility

Screening

Records after duplicates removed
(n =131)

Records screened
(n = 760)

Records excluded
(n =669)

Full-text articles assessed
for eligibility
(n = 91)

Full-text articles excluded,
with reasons
(n = 61)

Included

Studies included in
qualitative synthesis
(n = 30)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 30)

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The
PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097
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